SI-BONE, Inc. (NASDAQ:SIBN) Shares Bought by Bank of America Corp DE

Bank of America Corp DE lifted its position in shares of SI-BONE, Inc. (NASDAQ:SIBN - Free Report) by 25.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 138,915 shares of the company's stock after purchasing an additional 28,288 shares during the period. Bank of America Corp DE owned about 0.33% of SI-BONE worth $1,948,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Invesco Ltd. increased its stake in shares of SI-BONE by 8.9% in the fourth quarter. Invesco Ltd. now owns 17,203 shares of the company's stock worth $241,000 after buying an additional 1,413 shares during the last quarter. Rhumbline Advisers increased its stake in SI-BONE by 3.0% during the fourth quarter. Rhumbline Advisers now owns 57,621 shares of the company's stock valued at $808,000 after purchasing an additional 1,683 shares during the last quarter. Barclays PLC increased its stake in SI-BONE by 2.7% during the fourth quarter. Barclays PLC now owns 99,212 shares of the company's stock valued at $1,391,000 after purchasing an additional 2,589 shares during the last quarter. Alliancebernstein L.P. increased its stake in SI-BONE by 6.2% during the fourth quarter. Alliancebernstein L.P. now owns 55,750 shares of the company's stock valued at $782,000 after purchasing an additional 3,250 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD increased its stake in SI-BONE by 11.7% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 31,742 shares of the company's stock valued at $446,000 after purchasing an additional 3,318 shares during the last quarter. Institutional investors own 98.11% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on SIBN shares. Cantor Fitzgerald reiterated an "overweight" rating and set a $25.00 target price on shares of SI-BONE in a research note on Tuesday, May 6th. Needham & Company LLC reiterated a "buy" rating and set a $24.00 target price on shares of SI-BONE in a research note on Tuesday, May 6th. Finally, Truist Financial boosted their target price on shares of SI-BONE from $20.00 to $22.00 and gave the company a "buy" rating in a research note on Tuesday, May 6th.

Insider Activity

In related news, CFO Anshul Maheshwari sold 4,937 shares of the company's stock in a transaction dated Wednesday, May 7th. The shares were sold at an average price of $17.00, for a total value of $83,929.00. Following the completion of the sale, the chief financial officer now owns 265,356 shares of the company's stock, valued at $4,511,052. This represents a 1.83% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Anthony J. Recupero sold 3,311 shares of the company's stock in a transaction dated Wednesday, April 2nd. The stock was sold at an average price of $14.15, for a total transaction of $46,850.65. Following the completion of the sale, the insider now directly owns 284,555 shares of the company's stock, valued at $4,026,453.25. The trade was a 1.15% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 95,942 shares of company stock valued at $1,734,203. 4.00% of the stock is currently owned by company insiders.

SI-BONE Stock Performance

Shares of SIBN traded down $0.16 during midday trading on Friday, hitting $18.90. 485,058 shares of the stock traded hands, compared to its average volume of 382,655. SI-BONE, Inc. has a 1-year low of $11.70 and a 1-year high of $20.05. The firm has a market capitalization of $805.42 million, a PE ratio of -20.54 and a beta of 0.82. The company has a debt-to-equity ratio of 0.22, a quick ratio of 7.22 and a current ratio of 8.25. The business's 50 day moving average price is $16.10 and its two-hundred day moving average price is $15.52.

SI-BONE (NASDAQ:SIBN - Get Free Report) last announced its quarterly earnings results on Monday, May 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.09. SI-BONE had a negative net margin of 23.82% and a negative return on equity of 22.51%. The company had revenue of $47.29 million during the quarter, compared to the consensus estimate of $45.13 million. Equities research analysts predict that SI-BONE, Inc. will post -0.78 EPS for the current fiscal year.

About SI-BONE

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.